US Patent No: 5,539,082

Number of patents in Portfolio can not be more than 2000

Peptide nucleic acids

3 Status Updates

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

A novel class of compounds, known as peptide nucleic acids, bind complementary ssDNA and RNA strands more strongly than a corresponding DNA. The peptide nucleic acids generally comprise ligands such as naturally occurring DNA bases attached to a peptide backbone through a suitable linker.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • Assignment data not available. Check PTO

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Berg, Rolf H Strandvaenget 6, DK 2960 Rungsted Kyst, DK 14 601
Buchardt, Ole Sondergardsvej 73, DK 3500 Vaerlose, DK 32 704
Egholm, Michael Johnstrup Alle 3, DK 1923 Frederiksberg, DK 64 1937
Nielsen, Peter E Hjortevanget 509, DK 2980 Kokkedal, DK 29 642

Cited Art Landscape

Patent Info (Count) # Cites Year
 
MONSANTO COMPANY (1)
* 5,134,066 Improved probes using nucleosides containing 3-dezauracil analogs 198 1989
 
NEU-GENE DEVELOPMENT GROUP, A CORP. OF OR (1)
* 5,142,047 Uncharged polynucleotide-binding polymers 131 1987
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
Medical Research Fund of Tel Aviv (1)
* 2005/0221,326 Oligonucleotides antibodies and kits including same for treating prostate cancer and determining predisposition thereto 0 2004
 
Other [Check patent profile for assignment information] (19)
* 6,395,474 Peptide nucleic acids 33 1993
* 6,357,163 Use of nucleic acid analogues in diagnostics and analytical procedures 13 1994
* 6,713,602 Synthetic procedures for peptide nucleic acids 5 1995
* 6,710,163 Peptide nucleic acid synthons 3 1995
* 6,414,112 Peptide nucleic acids having 2,6-diaminopurine nucleobases 12 1996
* 6,710,164 Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility 1 1999
7,378,485 Peptide nucleic acids with polyamide-containing backbones 1 2002
* 2003/0211,509 TNF-delta ligand and uses thereof 0 2002
* 2004/0092,470 Dry powder oligonucleotide formualtion, preparation and its uses 45 2003
* 2006/0160,731 Peptide nucleic acids 1 2003
* 2007/0021,361 Methods and materials for modulating trpm2 0 2003
* 2007/0042,978 Nf-hev compositions and methods of use 16 2003
* 2005/0009,041 Peptide nucleic acids and synthetic procedures therefor 1 2004
* 2006/0046,255 Use of nucleic acid analogues in diagnostics and analytical procedures 0 2005
* 2006/0281,102 Methods for detecting genetic haplotypes by interaction with probes 0 2006
* 2006/0205,004 Reversible association of nucleic acid with a carboxylated substrate 0 2006
8,568,766 Peptides and peptide mimetics to treat pathologies associated with eye disease 0 2008
* 2011/0091,454 METHODS AND SYSTEMS FOR ANNOTATING BIOMOLECULAR SEQUENCES 5 2010
* 8,927,271 Compositions and methods for detecting target analytes 0 2011
 
Medical Research Fund of Tel Aviv Souraskv Medical Center (1)
8,076,087 Galectin sequences and compositions and methods utilizing same for treating or diagnosing arthritis and other chronic inflammatory diseases 0 2006
 
ARMUNE BIOSCIENCES, INC. (1)
* 2011/0237,461 USING PHAGE EPITOPES TO PROFILE THE IMMUNE RESPONSE 2 2011
 
INGENEUS INC. (23)
* 6,060,242 PNA diagnostic methods 22 1997
6,251,591 Quantitative method for detecting nucleotide concentration 47 1998
* 6,046,004 Solution hybridization of nucleic acids with antisense probes having modified backbones 33 1998
6,645,733 Fluorescent intensity method for assaying binding between proteins or peptides 10 1999
6,403,313 Fluorescent intensity assay for duplex and triplex nucleic acid hybridization solution utilizing fluorescent intercalators 4 1999
6,420,115 Cation mediated triplex hybridization assay 8 2000
6,911,536 Triplex and quadruplex catalytic hybridization 1 2000
6,927,027 Nucleic acid multiplex formation 5 2001
6,656,692 Parallel or antiparallel, homologous or complementary binding of nucleic acids or analogues thereof to form duplex, triplex or quadruplex complexes 3 2001
7,220,541 Homogeneous assay of biopolymer binding by means of multiple measurements under varied conditions 1 2001
* 2002/0137,056 Homogeneous assay of biopolymer binding by means of multiple measurements under varied conditions 2 2001
6,858,390 Aptamers containing sequences of nucleic acid or nucleic acid analogues bound homologously, or in novel complexes 2 2001
6,613,524 Amperometric affinity assay and electrically stimulated complexes of nucleic acids 5 2001
6,924,108 Nucleic acid binding enhancement by conjugation with nucleotides, nucleosides, bases and/or their analogues 2 2002
6,878,815 Heteropolymeric triplexes containing watson-crick triplets 2 2002
6,982,147 Apparatus for assaying biopolymer binding by means of multiple measurements under varied conditions 1 2002
* 2002/0123,066 Apparatus for assaying biopolymer binding by means of multiple measurements under varied conditions 0 2002
* 2003/0170,659 Electrical treatment of binding media to encourage, discourage and/or study biopolymer binding 2 2002
7,052,844 Purification of DS-DNA using heteropolymeric capture probes and a triplex, quadruplex or homologous duplex binding mechanism 2 2002
* 2003/0049,673 Purification of DS-DNA using heteropolymeric capture probes and a triplex, quadruplex or homologous duplex binding mechanism 3 2002
7,309,569 Parallel or antiparallel, homologous or complementary binding of nucleic acids or analogues thereof to form duplex, triplex or quadruplex complexes 0 2002
* 2003/0181,412 Method for modifying transcription and/or translation in an organism for therapeutic, prophylactic and/or analytic uses 6 2003
* 2003/0180,790 Electrically stimulated complexes of nucleic acids 2 2003
 
CELLSCRIPT, INC. (3)
7,413,857 Methods for using riboprimers for strand displacement replication of target sequences 9 2003
* 2004/0180,361 Methods for using riboprimers for strand displacement replication of target sequences 0 2003
7,659,072 Methods for using riboprimers for strand displacement replication of target sequences 0 2008
 
WISCONSIN ALUMNI RESEARCH FOUNDATION (1)
* 2004/0005,611 PNA probes, probe sets, methods and kits pertaining to the determination of Listeria 0 2003
 
NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT (2)
7,476,733 Development of a real-time PCR assay for detection of pneumococcal DNA and diagnosis of pneumococccal disease 3 2005
9,326,992 Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA 0 2012
 
HOECHST AKTIENGESELLSCHAFT (1)
* 6,121,418 PNA synthesis using a base-labile amino protecting group 1 1997
 
UNIVERSITY OF UTAH (2)
7,994,130 Compositions and methods for treating ocular pathologic angiogenesis and vascular permeability 0 2007
8,309,519 Compositions and methods for inhibiting vascular permeability 0 2011
 
ABBOTT MOLECULAR INC. (1)
9,365,902 Detection of bisulfite converted nucleotide sequences 0 2014
 
BIOCEPT, INC. (1)
6,433,134 Peptide nucleic acid precursors and methods of preparing same 13 2000
 
MCGILL UNIVERSITY (4)
8,278,103 Oligonucleotides comprising alternating segments and uses thereof 0 2003
* 2005/0142,535 Ogligonucleotides comprising alternating segments and uses thereof 29 2005
7,700,272 Polynucleotides encoding acetylcholine-gated chloride channel subunits of Caenorhabditis elegans 3 2005
* 2008/0260,750 Polynucleotides Encoding Acetylcholine-Gated Chloride Channel Subunits of Caenorhabditis Elegans 0 2005
 
SIGMA-ALDRICH CO. (6)
6,737,236 Bioconjugation of macromolecules 32 1999
7,427,678 Method for immobilizing oligonucleotides employing the cycloaddition bioconjugation method 16 2001
7,615,629 Methods and compositions for the tandem synthesis of two or more oligonucleotides on the same solid support 1 2002
* 2006/0149,046 Methods and compositions for the tandem synthesis of two or more oligonucleotides on the same solid support 23 2002
7,098,326 Methods for the integrated synthesis and purification of oligonucleotides 0 2003
* 2003/0195,351 Methods for the integrated synthesis and purification of oligonucleotides 1 2003
 
Sarepta Therapeutics, Inc. (7)
8,592,386 Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis 15 2009
8,697,858 Antisense antiviral compound and method for treating influenza viral infection 16 2010
8,779,128 Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups 17 2011
9,278,987 Functionally-modified oligonucleotides and subunits thereof 0 2012
9,066,967 Oligonucleotide analogues targeting human LMNA 0 2012
9,249,243 Antibacterial antisense oligonucleotide and method 0 2013
9,394,323 Antisense antiviral compound and method for treating influenza viral infection 0 2014
 
MERCK SHARP & DOHME CORP. (1)
6,171,794 Methods for determining cross-hybridization 7 1999
 
OHR PHARMACEUTICAL, INC. (1)
8,084,239 Preparation of a therapeutic composition 0 2009
 
GOLDMAN SACHS BANK USA (1)
* 2002/0146,717 Compositions, methods and kits for determining the presence of cryptosporidium parvum organisms in a test sample 0 2001
 
MS TECHNOLOGIES, LLC (1)
7,749,504 Anti-TAT188 antibodies 0 2007
 
The Regents of the University of California (1)
9,040,626 Nanofibers and morphology shifting micelles 0 2012
 
THE UNIVERSITY OF BRITISH COLUMBIA (2)
9,139,554 Amino lipids and methods for the delivery of nucleic acids 1 2009
9,205,102 Method for treatment of castration-resistant prostate cancer 0 2014
 
NABSYS 2.0 LLC (15)
* 2007/0190,542 HYBRIDIZATION ASSISTED NANOPORE SEQUENCING 65 2006
8,278,047 Biopolymer sequencing by hybridization of probes to form ternary complexes and variable range alignment 2 2008
8,882,980 Use of longitudinally displaced nanoscale electrodes for voltage sensing of biomolecules and other analytes in fluidic channels 0 2009
8,262,879 Devices and methods for determining the length of biopolymers and distances between probes bound thereto 10 2009
* 2010/0096,268 USE OF LONGITUDINALLY DISPLACED NANOSCALE ELECTRODES FOR VOLTAGE SENSING OF BIOMOLECULES AND OTHER ANALYTES IN FLUIDIC CHANNELS 13 2009
8,455,260 Tagged-fragment map assembly 4 2010
* 2010/0261,285 TAGGED-FRAGMENT MAP ASSEMBLY 2 2010
* 2010/0243,449 DEVICES AND METHODS FOR ANALYZING BIOMOLECULES AND PROBES BOUND THERETO 23 2010
8,246,799 Devices and methods for analyzing biomolecules and probes bound thereto 6 2010
* 2010/0310,421 DEVICES AND METHODS FOR ANALYZING BIOMOLECULES AND PROBES BOUND THERETO 13 2010
8,715,933 Assay methods using nicking endonucleases 5 2010
8,859,201 Methods for sequencing a biomolecule by detecting relative positions of hybridized probes 1 2011
8,926,813 Devices and methods for determining the length of biopolymers and distances between probes bound thereto 0 2012
9,051,609 Biopolymer Sequencing By Hybridization of probes to form ternary complexes and variable range alignment 0 2012
9,434,981 Assay methods using nicking endonucleases 0 2014
 
University of Washington (3)
7,138,259 PDEs and uses thereof 1 2001
7,598,067 PDEs and uses thereof 0 2006
* 2007/0116,705 NOVEL PDEs AND USES THEREOF 0 2006
 
YEDA RESEARCH AND DEVELOPMENT CO. LTD. (2)
7,176,181 Compositions and methods of using galectin-8 as an inhibitor of tumor cell growth 1 2002
7,416,725 Compositions and methods of using galectin-8 as an inhibitor of tumor cell growth 0 2006
 
Baltic Technology Development, Ltd. (1)
7,786,292 Antisense agents combining strongly bound base-modified oligonucleotide and artificial nuclease 0 2007
 
ANTISENSE PHARMA GMBH (2)
* 2007/0155,685 Pharmaceutical composition 11 2005
* 2011/0136,893 OLIGONUCLEOTIDE-, PROTEIN AND/OR PEPTIDE-POLYMER CONJUGATES 0 2007
 
BBM HOLDINGS, INC. (1)
* 2009/0305,944 Methods for Providing Palliative Care with AVR 118 1 2005
 
Atom Sciences, Inc. (1)
* 5,821,060 DNA sequencing, mapping, and diagnostic processes using hybridization chips and unlabeled DNA 31 1996
 
LIFE TECHNOLOGIES CORPORATION (20)
6,977,305 Modified carbocyanine dyes and their conjugates 84 2001
6,974,873 Modified carbocyanine dyes and their conjugates 59 2001
7,566,790 Intermediates and the synthesis of modified carbocyanine dyes and their conjugates 13 2005
* 2006/0004,188 Intermediates and the synthesis of modified carbocyanine dyes and their conjugates 33 2005
7,790,893 Modified carbocyanine dyes and their conjugates 11 2005
7,820,824 Modified carbocyanine dyes and their conjugates 9 2007
7,671,214 Modified carbocyanine dyes and their conjugates 11 2007
* 2007/0232,805 MODIFIED CARBOCYANINE DYES AND THEIR CONJUGATES 27 2007
* 2007/0178,511 MODIFIED CARBOCYANINE DYES AND THEIR CONJUGATES 26 2007
* 2007/0178,512 MODIFIED CARBOCYANINE DYES AND THEIR CONJUGATES 21 2007
8,614,302 Modified carbocyanine dyes and their conjugates 2 2008
7,927,830 Modified carbocyanine dyes and their conjugates 8 2008
* 2009/0035,809 Modified Carbocyanine Dyes and Their Conjugates 17 2008
* 2009/0035,810 MODIFIED CARBOCYANINE DYES AND THEIR CONJUGATES 9 2008
* 2011/0014,617 Methods and Systems for Detecting Nucleic Acids 0 2010
8,252,932 Modified carbocyanine dyes and their conjugates 4 2010
* 2011/0171,678 MODIFIED CARBOCYANINE DYES AND THEIR CONJUGATES 5 2010
8,569,506 Modified carbocyanine dyes and their conjugates 6 2012
9,018,396 Modified carbocyanine dyes and their conjugates 1 2013
9,423,323 Modified carbocyanine dyes and their conjugates 0 2015
 
COMPUGEN LTD. (5)
7,842,459 Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis 0 2005
8,415,455 Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics 1 2008
9,428,574 Polypeptides and uses thereof for treatment of autoimmune disorders and infection 0 2012
9,107,862 Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics 0 2013
9,375,466 Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics 0 2013
 
DUKE UNIVERSITY (9)
6,770,449 Methods of assaying receptor activity and constructs useful in such methods 6 2001
7,279,324 Nucleic acid encoding G-protein coupled receptor with modified DRY motif 0 2002
* 2003/0049,643 Constitutively desensitized G protein-coupled receptors 1 2002
* 2003/0182,669 Phosphoinositide 3-kinase mediated inhibition of GPCRs 3 2002
7,138,240 Methods of assaying receptor activity 5 2002
7,541,151 Single-cell biosensor for the measurement of GPCR ligands in a test sample 0 2002
7,572,888 Methods of assaying receptor activity and constructs useful in such methods 0 2004
* 2004/0209,308 Methods of assaying receptor activity and constructs useful in such methods 0 2004
* 2006/0026,702 Phosphoinositide 3-kinase mediated inhibition of GPCRs 5 2004
 
Gamida Cell Ltd. (6)
7,344,881 Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby 7 2003
7,955,852 Expansion of renewable stem cell populations 7 2004
8,846,393 Methods of improving stem cell homing and engraftment 0 2006
8,080,417 Methods of ex vivo hematopoietic stem cell expansion by co-culture with mesenchymal cells 5 2006
7,655,225 Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby 0 2008
9,175,266 Enhancement of natural killer (NK) cell proliferation and activity 0 2013
 
MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (1)
* 2001/0039,263 Chimeric oligonucleotides and the use thereof 53 2001
 
Genentech, Inc. (2)
6,872,704 Acidic mammalian proteins and polynucleotides encoding the same 0 2002
7,803,915 Antibody compositions for the diagnosis and treatment of tumor 1 2004
 
PROLIGO LLC (1)
* 6,001,966 Method for solution phase synthesis of oligonucleotides and peptides 13 1998
 
The United States of America as represented by the Secretary of the Navy (1)
8,691,729 Reaction discovery system 0 2008
 
MEDICAL UNIVERSITY OF SOUTH CAROLINA (1)
8,318,692 Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy 0 2011
 
IONIS PHARMACEUTICALS, INC. (1)
9,399,774 Modulation of transthyretin expression 0 2015
 
Immune Modulation Maximum (1)
* 5,849,196 Composition containing peptides and nucleic acids and methods of making same 8 1996
 
LORNE PARK RESEARCH USA, LLC (1)
* 5,846,729 Assaying nucleotides in solution using a fluorescent intensity quenching effect 51 1997
 
PROLIGO L.L.C., A LIMITED LIABILITY COMPANY OF DELAWARE (1)
* 5,874,532 Method for solution phase synthesis of oligonucleotides and peptides 23 1997
 
THE UAB RESEARCH FOUNDATION (2)
9,422,363 Synthetic apolipoprotein E mimicking polypeptides and methods of use 0 2008
8,557,767 Synthetic apolipoprotein E mimicking polypeptides and methods of use 0 2008
 
ISIS PHARMACEUTICALS, INC. (84)
* 6,077,833 Oligonucleotide compositions and methods for the modulation of the expression of B7 protein 23 1996
6,339,066 Antisense oligonucleotides which have phosphorothioate linkages of high chiral purity and which modulate .beta.I, .beta.II, .gamma., .delta., .EPSILON., .zeta. and .eta. isoforms of human protein kinase C 3 1997
* 6,015,887 Chiral peptide nucleic acids and methods for preparing same 10 1997
* 5,985,558 Antisense oligonucleotide compositions and methods for the inibition of c-Jun and c-Fos 40 1997
* 6,893,815 Nucleobase heterocyclic combinatorialization 0 1997
* 5,877,309 Antisense oligonucleotides against JNK 68 1997
7,321,828 System of components for preparing oligonucleotides 103 1998
* 6,117,847 Oligonucleotides for enhanced modulation of protein kinase C expression 3 1998
6,528,631 Oligonucleotide-folate conjugates 84 1998
6,300,319 Targeted oligonucleotide conjugates 36 1998
6,887,906 Compositions and methods for the delivery of oligonucleotides via the alimentary canal 41 1998
* 6,277,603 PNA-DNA-PNA chimeric macromolecules 5 1998
6,221,850 Antisense oligonucleotide compositions and methods for the modulation of JNK proteins 9 1998
6,175,004 Process for the synthesis of oligonucleotides incorporating 2-aminoadenosine 4 1998
6,225,293 Methods and compounds for tracking the biodistribution of macromolecule-carrier combinations 0 1998
* 6,069,243 Process for oligonucleotide synthesis 15 1998
6,492,111 In situ binary synthesis of biologically effective molecules 0 1998
6,300,320 Modulation of c-jun using inhibitors of protein kinase C 0 1999
6,399,765 Methods for removing dimethoxytrityl groups from oligonucleotides 3 1999
6,335,434 Nucleosidic and non-nucleosidic folate conjugates 125 1999
* 6,133,246 Antisense oligonucleotide compositions and methods for the modulation of JNK proteins 103 1999
8,153,602 Composition and methods for the pulmonary delivery of nucleic acids 1 1999
6,841,539 Compositions and methods for topical delivery of oligonucleotides 18 1999
6,319,906 Oligonucleotide compositions and methods for the modulation of the expression of B7 protein 14 1999
6,656,730 Oligonucleotides conjugated to protein-binding drugs 78 1999
* 6,613,873 Peptide nucleic acids having 2,6-diaminopurine nucleobases 2 1999
6,593,466 Guanidinium functionalized nucleotides and precursors thereof 12 1999
6,312,900 Antisense oligonucleotide compositions and methods for the modulation of activating protein 1 18 1999
6,753,423 Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals 10 2000
6,762,169 Ligand-conjugated oligomeric compounds 55 2000
6,534,639 Guanidinium functionalized oligonucleotides and method/synthesis 23 2000
6,809,193 Antisense oligonucleotide compositions and methods for the modulation of JNK proteins 15 2001
6,525,031 Targeted Oligonucleotide conjugates 25 2001
6,861,514 Nucleosidic and non-nucleosidic folate conjugates 45 2001
6,537,973 Oligonucleotide inhibition of protein kinase C 8 2001
6,747,014 Compositions and methods for non-parenteral delivery of oligonucleotides 52 2001
6,921,812 Methods of modulating pharmacokinetics of oligonucleotides 2 2002
7,695,902 Oligoribonucleotides and ribonucleases for cleaving RNA 65 2002
* 2003/0191,075 Method of using modified oligonucleotides for hepatic delivery 47 2002
6,794,502 Methods for removing dimethoxytrityl groups from oligonucleotides 0 2002
* 2003/0207,804 Modified peptide nucleic acids 15 2002
7,038,037 Method for sequential support-bound synthesis of conjugated oligomeric compounds 0 2002
* 2002/0192,700 In situ binary synthesis of biologically effective molecules 0 2002
6,914,148 Guanidinium functionalized intermediates 3 2002
* 2004/0063,618 Peptide nucleic acids having improved uptake and tissue distribution 4 2002
6,660,720 Targeted oligonucleotide conjugates 6 2002
7,002,006 Protection of nucleosides 2 2003
7,169,916 Chloral-free DCA in oligonucleotide synthesis 48 2003
* 2004/0023,917 Oligonucleotide compositions and methods for the modulation of the expression of B7 protein 0 2003
7,235,653 Oligonucleotide compositions and methods for the modulation of the expression of B7 protein 46 2003
* 2004/0235,164 Oligonucleotide compositions and methods for the modulation of the expression of B7 protein 1 2003
9,096,636 Chimeric oligomeric compounds and their use in gene modulation 0 2003
8,604,183 Compositions comprising alternating 2′-modified nucleosides for use in gene modulation 0 2003
7,812,149 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations 2 2003
* 2004/0142,899 Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals 0 2004
8,394,947 Positionally modified siRNA constructs 0 2004
7,960,355 Compositions and methods for the modulation of the expression of B7 protein 0 2004
7,276,599 Oligonucleotide synthesis with alternative solvents 48 2004
* 2005/0026,192 Oligonucleotide synthesis with alternative solvents 2 2004
8,703,728 Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini 0 2004
8,778,900 Modulation of eIF4E-BP1 expression 0 2005
7,468,431 Modulation of eIF4E-BP2 expression 50 2005
8,569,474 Double stranded constructs comprising one or more short strands hybridized to a longer strand 0 2005
7,884,086 Conjugates for use in hepatocyte free uptake assays 3 2005
8,377,897 Compositions and methods for non-parenteral delivery of oligonucleotides 1 2005
7,745,609 Antisense modulation of CD40 expression 45 2006
7,807,652 Modulation of eIF4E-BP2 expression 1 2006
* 2007/0149,472 ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE MODULATION OF JNK PROTEINS 0 2006
8,129,515 Oligomeric compounds and compositions for the use in modulation of microRNAs 6 2007
7,759,480 Chloral-free DCA in oligonucleotide synthesis 0 2007
* 2007/0123,703 CHLORAL-FREE DCA IN OLIGONUCLEOTIDE SYNTHESIS 0 2007
7,897,582 Oligonucleotide compositions and methods for the modulation of the expression of B7 protein 0 2007
* 2008/0027,019 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE MODULATION OF THE EXPRESSION OF B7 PROTEIN 2 2007
8,198,253 Compositions and their uses directed to HBXIP 0 2007
8,101,585 Compositions and methods for the modulation of JNK proteins 1 2007
* 2008/0255,030 COMPOSITIONS AND METHODS FOR THE MODULATION OF JNK PROTEINS 3 2007
8,101,743 Modulation of transthyretin expression 7 2008
8,067,386 Modulation of eIF4E-BP2 expression 0 2008
8,916,531 Modulation of CD40 expression 0 2008
7,964,579 Compositions and methods for topical delivery of oligonucleotides 2 2009
9,127,272 Oligomeric compounds and compositions for the use in modulation of target nucleic acids 0 2012
8,691,785 Compositions and methods for non-parenteral delivery of oligonucleotides 27 2013
8,697,860 Diagnosis and treatment of disease 2 2013
9,061,044 Modulation of transthyretin expression 0 2014
 
THIEN, DOUGLAS Y. (1)
6,303,799 Polynucleotide crosslinking agents 4 1998
 
ALT Solutions Inc. (3)
* 2009/0099,060 Modulation of line-1 reverse transcriptase 0 2005
8,778,906 Modulation of line-1 reverse transcriptase 0 2008
* 2009/0036,391 Modulation of line-1 reverse transcriptase 0 2008
 
PALADIN LABS INC. (1)
9,090,649 Oligonucleotide duplexes comprising DNA-like and RNA-like nucleotides and uses thereof 0 2009
 
Active Motif (4)
7,115,738 Hydroxyproline/phosphono oligonucleotide analogues, methods of synthesis and methods of use 0 2001
6,962,906 Oligonucleotide analogues, methods of synthesis and methods of use 10 2002
* 2003/0059,789 Oligonucleotide analogues, methods of synthesis and methods of use 4 2002
* 2004/0014,644 Oligonucleotide analogues and methods of use for modulating gene expression 1 2003
 
DAKOCYTOMATION A/S (1)
* 2003/0129,626 Methods, kits and compositions pertaining to the suppression of detectable probe binding to randomly distributed repeat sequences in genomic nucleic acid 7 2002
 
NORTHWESTERN UNIVERSITY (9)
8,252,756 Nucleic acid functionalized nanoparticles for therapeutic applications 2 2006
8,507,200 Particles for detecting intracellular targets 0 2008
7,807,372 Screening sequence selectivity of oligonucleotide-binding molecules using nanoparticle based colorimetric assay 0 2008
* 2008/0311,669 SCREENING SEQUENCE SELECTIVITY OF OLIGONUCLEOTIDE-BINDING MOLECULES USING NANOPARTICLE BASED COLORIMETRIC ASSAY 2 2008
8,481,760 Inhibition and treatment of prostate cancer metastasis 0 2009
9,139,827 Polyvalent RNA-nanoparticle compositions 0 2009
9,376,690 Templated nanoconjugates 0 2010
8,999,947 Nucleic acid functionalized nanoparticles for therapeutic applications 0 2012
8,742,141 Inhibition and treatment of prostate cancer metastasis 0 2013
 
EMERALD THERAPEUTICS, INC. (1)
9,289,502 Preparation of oligo conjugates 0 2013
 
DRUG ROYALTY TRUST 9 (3)
6,660,845 Non-aggregating, non-quenching oligomers comprising nucleotide analogues; methods of synthesis and use thereof 55 1999
6,972,328 Non-aggregating non-quenching oligomer comprising nucelotide analogs, method of synthesis and use thereof 2 2003
* 2004/0116,689 Non-aggregating non-quenching oligomer comprising nucelotide analogs, method of synthesis and use thereof 36 2003
 
UNIVERSITE LAVAL (5)
7,709,207 Method for identifying compounds for treatment of pain 0 2004
* 2007/0092,510 Cns chloride modulation and uses thereof 3 2004
7,718,382 Method for identifying compounds for treatment of pain 4 2005
* 2008/0260,718 Phospholipase C Gamma Modulation and Uses Thereof for Management of Pain and Nociception 0 2005
8,173,376 Method for identifying compounds for treatment of pain 0 2010
 
Neilsen, Peter E. (1)
6,686,442 Conjugated peptide nucleic acids having enhanced cellular uptake 0 2001
 
ARROWHEAD RESEARCH CORPORATION (7)
* 2010/0197,773 COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF PTP1B GENES 3 2010
* 2011/0020,300 COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF GLUCOCORTICOID RECEPTOR (GCR) GENES 0 2010
* 2011/0112,176 COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF KIF10 GENES 0 2010
* 2011/0152,349 COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF IL-18 GENES 0 2010
* 2011/0196,016 Compositions and Methods for Inhibiting Expression of IKK2 Genes 0 2011
8,946,176 Compositions and methods for inhibiting expression of RRM2 genes 0 2011
8,809,293 Compositions and methods for inhibiting gene expression of hepatitis B virus 3 2012
 
BECTON, DICKINSON AND COMPANY (1)
9,404,160 Methods for the detection of microorganisms 0 2010
 
THE REGENTS OF THE UNIVERSITY OF MICHIGAN (25)
6,680,172 Treatments and markers for cancers of the central nervous system 0 2000
* 2006/0073,125 Isolation and use of solid tumor stem cells 29 2005
* 2007/0099,209 Compositions and methods for treating and diagnosing cancer 35 2006
7,850,961 Methods for targeting solid tumor stem cells in a solid tumor using a notch4 receptor antagonist 17 2006
8,652,467 Dek protein compositions and methods of using the same 0 2006
* 2009/0004,197 Dek Protein Compositions and Methods of Using the Same 3 2006
7,723,112 Compositions and methods for treating and diagnosing cancer 9 2006
* 2008/0064,049 Compositions and methods for treating and diagnosing cancer 31 2006
* 2007/0212,737 Isolation and use of solid tumor stem cells 27 2006
* 2008/0019,961 Hedgehog signaling pathway antagonist cancer treatment 26 2007
7,713,710 Isolation and use of solid tumor stem cells 15 2007
8,044,259 Determining the capability of a test compound to affect solid tumor stem cells 1 2007
8,148,147 Compositions and methods for treating and diagnosing pancreatic cancer 0 2008
* 2008/0261,244 Compositions And Methods For Treating And Diagnosing Pancreatic Cancer 6 2008
* 2008/0292,546 COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING CANCER 8 2008
* 2008/0260,734 COMPOSITIONS AND METHODS FOR CHARACTERIZING, REGULATING, DIAGNOSING, AND TREATING CANCER 16 2008
7,939,263 Compositions and methods for treating and diagnosing cancer 2 2009
* 2010/0169,990 COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING CANCER 3 2009
* 2011/0033,481 PROSPECTIVE IDENTIFICATION AND CHARACTERIZATION OF BREAST CANCER STEM CELLS 14 2010
9,267,133 Phage microarray profiling of the humoral response to disease 0 2010
* 2011/0092,378 ISOLATION AND USE OF SOLID TUMOR STEM CELLS 14 2010
* 2011/0183,866 COMPOSITIONS AND METHODS FOR TREATING AND DIAGNOSING CANCER 5 2011
8,420,885 Determining the capability of a test compound to affect solid tumor stem cells 0 2011
8,501,472 Compositions and methods for treating and diagnosing pancreatic cancer 0 2012
9,089,556 Method for treating cancer using an antibody that inhibits notch4 signaling 0 2013
 
PHIGENIX, INC. (8)
7,964,577 Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy 0 2006
8,080,534 Targeting PAX2 for the treatment of breast cancer 1 2010
8,735,365 Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy 0 2011
8,431,546 Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy 0 2011
8,394,780 Targeting PAX2 for the treatment of breast cancer 0 2011
8,633,149 Targeting PAX2 for the treatment of breast cancer 0 2011
8,461,101 Targeting PAX2 for the treatment of breast cancer 0 2011
8,653,021 Targeting PAX2 for the treatment of breast cancer 0 2011
 
CYTYC CORPORATION (4)
6,936,443 Detection and typing of human papillomavirus using PNA probes 11 2002
* 2003/0143,529 Detection and typing of human papillomavirus using PNA probes 2 2002
7,803,530 Detection and typing of human papillomavirus using PNA probes 0 2002
* 2003/0108,866 Detection and typing of human papillomavirus using PNA probes 1 2002
 
PNA DIAGNOSTICS A/S (2)
* 5,861,250 Protecting nucleic acids and methods of analysis 9 1996
* 6,346,378 Nucleic acid analogs with a chelating functionality 0 1998
 
SYMYX TECHNOLOGIES, INC. (1)
* 2005/0158,879 Polymer brushes for immobilizing molecules to a surface and having water-soluble or water-dispersible segments therein and probes bonded thereto 0 2004
 
REGENTS OF THE UNIVERSITY OF MINNESOTA (2)
7,741,304 Casein kinase 2 antisense therapy 0 2007
* 2008/0113,932 CASEIN KINASE 2 ANTISENSE THERAPY 0 2007
 
Nielsen, Peter E. (5)
7,569,659 Admixture comprising a target molecule and a nucleic acid mimic comprising sterically bulky substituents 0 1997
6,190,866 Methods of bacterial gene function determination using peptide nucleic acids 2 1998
6,350,853 Conjugated peptide nucleic acids having enhanced cellular uptake 11 1999
* 6,770,738 Higher order structure and binding of peptide nucleic acids 1 1999
6,734,161 Peptide nucleic acids having antibacterial activity 0 2000
 
OncoMed Pharmaceuticals (2)
8,551,789 Frizzled-binding agents and their use in screening for WNT inhibitors 8 2011
9,228,013 Methods of using the FRI domain of human frizzled receptor for inhibiting Wnt signaling in a tumor or tumor cell 0 2014
 
EPICENTRE TECHNOLOGIES CORPORATION (1)
* 2004/0197,802 Methods for using primers that encode one strand of a double-stranded promoter 38 2003
 
University of Massachusetts (2)
7,794,951 SREBP2gc transcription factors and uses thereof 0 2005
* 2007/0089,179 SREBP2gc transcription factors and uses thereof 0 2005
 
AGILIX CORPORATION (1)
8,043,834 Universal reagents for rolling circle amplification and methods of use 0 2003
 
UNIVERSITY OF MARYLAND, BALTIMORE (1)
* 2006/0281,121 Computing with biomolecules 4 2006
 
EMD MILLIPORE CORPORATION (1)
7,091,348 Fluorescent dyes, energy transfer couples and methods 19 2003
 
HALO-BIO RNAI THERAPEUTICS, INC. (1)
9,200,276 Polynucleotides for multivalent RNA interference, compositions and methods of use thereof 0 2010
 
GILEAD SCIENCES, INC. (1)
* 5,763,424 Composition and method for storing nucleotide analogs 0 1996
 
PROMEGA CORPORATION (1)
8,309,059 Reactive cyanine compounds 0 2010
 
LUMINEX CORPORATION (1)
8,324,359 Oxocarbonamide peptide nucleic acids and methods of using same 0 2007
 
ADVANDX, INC. (4)
* 8,795,972 Reagents, methods and kits for classification of fungi and direction of anti-fungal therapy 0 2008
* 2009/0092,994 Reagents, methods and kits for classification of fungi and direction of anti-fungal therapy 0 2008
8,586,314 (sensu stricto) 0 2010
* 2010/0285,987 PEPTIDE NUCLEIC ACID PROBES FOR DETECTION, IDENTIFICATION AND/OR QUANTITATION OF PSEUDOMONAS (SENSU STRICTO) 0 2010
 
AVI BIOPHARMA, INC. (1)
* 6,060,246 Reagent and method for isolation and detection of selected nucleic acid sequences 78 1997
 
QIAGEN GMBH (14)
6,977,148 Multiple displacement amplification 102 2001
* 2004/0161,742 Nucleic acid amplification 11 2001
6,617,137 Method of amplifying whole genomes without subjecting the genome to denaturing conditions 67 2001
7,553,619 Detection method using dissociated rolling circle amplification 2 2002
7,074,600 Amplification of denatured and stabilized nucleic acids 15 2002
* 2004/0121,338 Real-time detection of rolling circle amplification products 5 2002
* 2003/0165,948 Method and compositions for efficient and specific rolling circle amplification 6 2002
6,977,153 Rolling circle amplification of RNA 36 2002
* 2004/0126,770 Rolling circle amplification of RNA 4 2002
7,297,485 Method for nucleic acid amplification that results in low amplification bias 27 2003
7,955,795 Method of whole genome amplification with reduced artifact production 2 2003
* 2004/0248,105 Method of whole genome amplification with reduced artifact production 7 2003
8,309,303 Reverse transcription and amplification of RNA with simultaneous degradation of DNA 0 2006
* 2008/0128,298 NUCLEIC ACID AMPLIFICATION 1 2007
 
BOSTON PROBEE, INC. (1)
7,422,852 Detection of nucleic acid using linear beacons 2 2003
 
GEN-PROBE INCORPORATED (20)
6,821,770 Polynucleotide matrix-based method of identifying microorganisms 26 2000
6,376,186 Polynucleotide probes for detection and quantitation of staphylococcus 7 2000
6,326,486 Polynucleotide probes for detection and quantitation of bacteria in the family enterobacteriaceae 4 2000
6,235,484 Polynucleotide probes for detection and quantitation of actinomycetes 6 2000
* 2003/0045,488 Antisense oligonucleotides comprising universal and/or degenerate bases 7 2001
7,081,527 Compositions, methods and kits for determining the presence of Cryptosporidium parvum organisms in a test sample 6 2001
7,790,877 Antisense oligonucleotides with increased RNase sensitivity 0 2002
* 2003/0165,888 Oligonucleotide probes and primers comprising universal bases for diagnostic purposes 0 2002
8,153,772 Oligonucleotide probes and primers comprising universal bases for diagnostic purposes 0 2003
* 2003/0170,711 Oligonucleotide probes and primers comprising universal bases for diagnostic purposes 5 2003
8,679,789 Oligonucleotides comprising a molecular switch 0 2004
* 2005/0042,638 Oligonucleotides comprising a molecular switch 8 2004
7,449,328 Probe matrix-based device for identifying microorganisms 1 2004
7,585,631 Method for obtaining purified RNA from viable oocysts 2 2006
* 2007/0020,661 METHOD FOR OBTAINING PURIFIED RNA FROM VIABLE OOCYSTS 0 2006
8,927,703 0 2008
8,703,421 0 2009
8,008,017 Compositions and methods for detecting the presence of cryptosporidium organisms in a test sample 1 2009
8,105,779 in a test sample 0 2011
9,243,286 Methods of using oligonucleotides comprising a molecular switch 0 2014
 
Panagene, Inc. (1)
* 2010/0240,058 MicroRNA Antisense PNAs, Compositions Comprising the Same, and Methods for Using and Evaluating the Same 0 2008
 
NANOSTRING TECHNOLOGIES, INC. (1)
* 2011/0201,515 COMPOSITIONS AND METHODS FOR THE DETECTION OF SMALL RNAS 0 2011
 
HOFFMANN-LA ROCHE INC. (1)
* 2010/0124,547 COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF FACTOR VII GENES 1 2009
 
The Trustees of Columbia University in the City of New York (2)
* 2003/0082,140 Combinatorial methods for inducing cancer cell death 3 2001
7,329,649 Combinatorial methods for inducing cancer cell death 0 2004
 
VECTOR TOBACCO INC. (1)
9,439,452 Reduced risk tobacco products and methods of making same 0 2013
 
The United States of America as represented by the Department of Veterans Affairs (1)
* 2005/0043,262 Novel specific inhibitor of the cyclin kinase inhibitor p21Waf1/Cip1 and methods of using the inhibitor 1 2004
 
GEISINGER CLINIC (1)
* 2006/0154,285 Zebrafish heterotrimer G-protein gamma 2 subunit (GNG2) 1 2005
 
BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (1)
* 5,844,110 Synthetic triple helix-forming compound precursors 7 1995
 
LONZA COLOGNE GMBH (1)
6,521,456 Cellular transport system for the transfer of a nucleic acid through the nuclear envelope and methods thereof 3 2001
 
YALE UNIVERSITY (10)
* 2004/0115,643 Thermodynamic equilibrium extension of primers 3 2002
7,794,931 Riboswitches, methods for their use, and compositions for use with riboswitches 10 2003
* 2005/0053,951 Riboswitches, methods for their use, and compositions for use with riboswitches 10 2003
7,618,776 Rolling circle replication reporter systems 5 2004
8,313,901 Methods and compositions related to the modulation of riboswitches 0 2006
* 2009/0305,253 Methods and Compositions Related to the Modulation of Riboswitches 1 2006
* 2010/0286,082 RIBOSWITCHES AND METHODS AND COMPOSITIONS FOR USE OF AND WITH RIBOSWITCHES 1 2008
8,309,356 Pseudocomplementary oligonucleotides for targeted gene therapy 0 2010
8,440,810 Riboswitches, methods for their use, and compositions for use with riboswitches 0 2011
* 2011/0150,854 RIBOSWITCHES, METHODS FOR THEIR USE, AND COMPOSITIONS FOR USE WITH RIBOSWITCHES 0 2011
 
BRISTOL-MYERS SQUIBB COMPANY (7)
* 2002/0068,346 Modified inosine 5'-monophosphate dehydrogenase polypeptides and uses thereof 5 2001
8,227,420 Method for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID 3 2010
8,148,332 Method for treating a rheumatic disease using a soluble TLA4 molecule 3 2011
8,497,247 Methods for treating type I diabetes mellitus by administering a soluble CTLA4 molecule 3 2012
8,722,632 Methods for treating Sjogrens syndrome by administering a soluble CTLA4 molecule 0 2013
8,703,718 Methods for treating juvenile rheumatoid arthritis by administering a soluble CTLA4 molecule 0 2013
9,296,808 Methods for treating scleroderma by administering a soluble CTLA4 molecule 0 2014
 
OnCoimmunin, Inc. (4)
6,936,687 Compositions for the detection of enzyme activity in biological samples and methods of use thereof 15 1999
7,541,143 Homo-doubly labeled compositions for the detection of enzyme activity in biological samples 1 2004
7,879,574 Compositions for the detection of enzyme activity in biological samples and methods of use thereof 0 2007
* 2008/0199,898 COMPOSITIONS FOR THE DETECTION OF ENZYME ACTIVITY IN BIOLOGICAL SAMPLES AND METHODS OF USE THEREOF 6 2007
 
AMERSHAM PLC (3)
6,656,700 Isoforms of human pregnancy-associated protein-E 3 2001
* 2004/0068,380 Human gtp-rho binding protein 2 0 2003
* 2004/0063,134 Novel isoforms of human pregnancy-associated protein-E 0 2003
 
ONCOMED PHARMACEUTICALS, INC. (9)
8,324,361 Nucleic acid molecules encoding soluble frizzled (FZD) receptors 0 2010
9,157,904 Wnt antagonists and methods of treatment and screening 0 2011
8,507,442 Methods of use for an antibody against human frizzled receptors 1, 2. 5, 7 or 8 8 2011
8,765,913 Human frizzled (FZD) receptor polypeptides and methods of use thereof for treating cancer and inhibiting growth of tumor cells 0 2012
9,273,139 Monoclonal antibodies against frizzled 0 2013
8,975,044 Polynucleotides encoding for frizzled-binding agents and uses thereof 0 2013
9,266,959 Methods of treating neuroendocrine tumors using frizzled-binding agents 0 2013
9,359,444 Methods and monitoring of treatment with a Wnt pathway inhibitor 0 2014
9,168,300 MET-binding agents and uses thereof 0 2014
 
Arcxis Biotechnologies (1)
* 2008/0182,759 SELECTION OF APTAMERS BASED ON GEOMETRY 2 2007
 
UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (1)
8,022,046 Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes 0 2009
 
Bayer Aktiengesellschaft (1)
* 5,849,893 Nucleic acid-binding oligomers possessing C-branching for therapy and diagnostics 3 1996
 
EXIQON A/S (4)
* 2009/0137,504 MICRORNA TARGET SITE BLOCKING OLIGOS AND USES THEREOF 7 2007
* 2009/0053,718 NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF microRNAs AND THEIR TARGET mRNAs 11 2008
* 2009/0326,049 BLOCKING OLIGOS FOR INHIBITION OF MICRORNA AND SIRNA ACTIVITY AND USES THEREOF 14 2009
* 2010/0113,284 SMALL INTERFERING RNA (SIRNA) TARGET SITE BLOCKING OLIGOS AND USES THEREOF 3 2009
 
AVENTIS PHARMA DEUTSCHLAND GMBH (1)
6,316,595 PNA synthesis using a base-labile amino protecting group 0 2000
 
DEUTSCHES KREBSFORSCHUNGSZENTRUM (1)
* 6,673,544 Method for the light-controlled synthesis of biochips 1 2001
 
ROBERT BOSCH GMBH (1)
8,463,526 Method for detecting a periodically pulsing operating parameter 0 2008
 
INTEL CORPORATION (2)
* 2005/0064,435 Programmable molecular barcodes 13 2003
* 2006/0199,216 Programmable molecular barcodes 1 2006
 
GE HEALTHCARE LIMITED (1)
6,686,188 Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle 0 2001
 
HOLOGIC, INC. (1)
* 2009/0253,142 COMPOSITIONS AND METHODS FOR ANALYSIS OF NUCLEIC ACID MOLECULES DURING AMPLIFICATION REACTIONS 16 2009
 
NIELSEN, PETER (5)
* 6,451,968 Peptide nucleic acids 9 1994
* 7,223,833 Peptide nucleic acid conjugates 10 1994
6,617,422 Peptide nucleic acid monomers and oligomers 4 1997
6,300,318 Antibacterial and antibiotic methods using peptide nucleic acids and pharmaceutical compositions therefor 1 1997
* 6,632,919 Peptide nucleic acid monomers and oligomers 3 1998
 
Capitol Genomix, Inc. (2)
7,052,840 Reversible association of nucleic acid with a carboxylated substrate 0 2002
* 2003/0194,707 Reversible association of nucleic acid with a carboxylated substrate 0 2002
 
The Penn State Research Foundation (1)
* 5,968,748 Antisense oligonucleotide modulation of human HER-2 expression 37 1998
 
Codexis, Inc. (1)
8,614,081 Nitrilase biocatalysts 0 2010
 
AXOLABS GMBH (1)
* 2011/0201,006 Oligonucleotide Detection Method 0 2009
 
FREESLATE, INC. (3)
6,692,914 Polymer brushes for immobilizing molecules to a surface or substrate, where the polymers have water-soluble or water-dispersible segments and probes bonded thereto 34 2000
6,833,276 Polymer brushes for immobilizing molecules to a surface and having water-soluble or water-dispersible segments therein and probes bonded thereto 11 2001
7,205,161 Polymer brushes for immobilizing molecules to a surface or substrate having improved stability 2 2002
 
ELITECH HOLDING B.V. (2)
9,085,800 Functionalized 3-alkynyl pyrazolopyrimidine analogues as universal bases and methods of use 0 2012
8,969,003 Functionalized 3-alkynyl pyrazolopyrimidine analogues as universal bases and methods of use 0 2013
 
MEDTRONIC, INC. (5)
7,320,965 Compositions and methods for inhibiting expression of Huntingtin gene 83 2006
* 2007/0099,860 Compositions and methods for inhibiting expression of huntingtin gene 9 2006
7,749,978 Compositions and methods for inhibiting expression of Huntingtin gene 47 2007
* 2008/0221,055 COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HUNTINGTIN GENE 3 2007
8,314,075 Compositions and methods for inhibiting expression of huntingtin gene 0 2011
 
MASSACHUSETTS INSTITUTE OF TECHNOLOGY (3)
8,445,228 Enhancement of in vitro translation by nanoparticle conjugates 1 2009
* 2011/0117,597 Enhancement of in vitro translation by nanoparticle conjugates 0 2009
9,388,445 Enhancement of in vitro translation by nanoparticle conjugates 0 2013
 
Cold Spring Harbor Laboratory (1)
* 2005/0054,836 Chimeric molecules to modulate gene expression 7 2003
 
MICROSOFT TECHNOLOGY LICENSING, LLC (1)
* 2003/0222,908 Dynamic wizard interface system and method 3 2002
 
APPLIED BIOSYSTEMS, LLC (37)
6,485,901 Methods, kits and compositions pertaining to linear beacons 48 1998
* 6,355,421 Methods, kits and compositions pertaining to PNA molecular beacons 72 1998
* 6,326,479 Synthetic polymers and methods, kits or compositions for modulating the solubility of same 12 1999
6,361,942 Method, kits and compositions pertaining to detection complexes 15 1999
* 6,331,618 Compositions of solvents and high concentrations of nucleic acid analogs 4 1999
6,441,152 Methods, kits and compositions for the identification of nucleic acids electrostatically bound to matrices 5 1999
7,060,432 Methods for the detection, identification, and/or enumeration of yeast, particularly in wine 1 2000
7,981,599 Non-nucleic acid probes, probe sets, methods and kits pertaining to the detection of individual human chromosomes X, Y, 1, 2, 3, 4, 6, 7, 8, 9, 10, 11, 12, 16, 17, 18 and 20 as 13/21 as a pair 0 2000
6,607,889 Methods, kits and compositions pertaining to detection complexes 8 2001
6,528,267 Methods, kits and compositions pertaining to PNA molecular beacons 12 2001
6,649,349 In-situ methods for analyzing target sequences using linear beacons 4 2001
6,770,442 Methods for modulating the solubility of synthetic polymers 0 2001
6,905,824 Methods for determining organisms not requiring the separation of fixative or excess probe 0 2001
* 2003/0165,856 Methods for determining organisms not requiring the separation of fixative or excess probe 0 2001
7,256,275 Methods, kits and compositions pertaining to combination oligomers and libraries for their preparation 5 2002
* 2003/0211,483 Methods for the enrichment of low-abundance polynucleotides 8 2002
6,949,343 Methods, kits and compositions pertaining to PNA Molecular Beacons 1 2003
* 2003/0232,327 Methods, kits and compositions pertaining to PNA Molecular Beacons 0 2003
* 8,017,758 PNA oligomers, oligomer sets, methods and kits pertaining to the detection of Bacillus anthracis 2 2003
* 2004/0014,105 Methods for the enrichment of low-abundance polynucleotides 10 2003
7,816,501 Compositions comprising a linked acceptor moiety 0 2003
* 2009/0270,602 Compositions comprising a linked acceptor moiety 1 2003
* 2006/0014,191 Analog probe complexes 8 2005
* 2006/0292,586 ID-tag complexes, arrays, and methods of use thereof 8 2005
7,674,585 Methods, kits and compositions pertaining to combination oligomers and libraries for their preparation 2 2006
7,638,279 Methods, kits and compositions pertaining to combination oligomers and libraries for their preparation 1 2006
* 2008/0125,332 Methods, Kits and Compositions Pertaining to Combination Oligomers and Libraries for Their Preparation 0 2006
7,884,053 Methods, kits and compositions pertaining to combination oligomers and libraries for their preparation 0 2006
7,851,155 Methods, kits and compositions pertaining to combination oligomers and libraries for their preparation 0 2006
7,745,126 Methods, kits and compositions pertaining to combination oligomers and libraries for their preparation 1 2006
7,605,253 Methods, kits and compositions pertaining to combination oligomers and libraries for their preparation 0 2006
7,566,420 Methods, kits and compositions pertaining to combination oligomers and libraries for their preparation 0 2006
* 2008/0085,837 Methods, Kits and Compositions Pertaining to Combination Oligomers and Libraries for Their Preparation 2 2006
* 2007/0105,145 Methods, Kits and Compositions Pertaining to Combination Oligomers and Libraries for Their Preparation 0 2006
* 2008/0241,838 METHODS AND SYSTEMS FOR DETECTING NUCLEIC ACIDS 2 2007
* 2008/0193,940 SYSTEMS AND METHODS FOR DETECTING NUCLEIC ACIDS 1 2007
7,892,741 Methods, kits and compositions pertaining to linear beacons 1 2008
 
Q-RNA, INC. (2)
* 2006/0199,194 Methods of detection using immuno-Q-Amp technology 0 2005
* 2006/0024,736 Methods of detection employing immuno-Q-Amp technology 0 2005
 
Oncolmmunin, Inc. (2)
6,893,868 Homo-doubly labeled compositions for the detection of enzyme activity in biological samples 7 2000
7,312,302 Compositions for the detection of enzyme activity in biological samples and methods of use thereof 2 2001
 
WILLIAM MARSH RICE UNIVERSITY (1)
* 2011/0045,080 Single-Walled Carbon Nanotube/Bioactive Substance Complexes and Methods Related Thereto 9 2010
 
MORPHOTEK, INC. (2)
7,754,450 Methods of generating high-production of antibodies from hybridomas created by in vitro immunization 2 2003
8,445,229 Methods of generating high-production of antibodies from hybridomas created by in vitro immunization 0 2010
 
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (1)
6,960,457 Reversible immobilization of arginine-tagged moieties on a silicate surface 5 2000
 
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (6)
6,472,209 Using polyamide nucleic acid oligomers to engender a biological response 2 1997
6,743,627 Using polyamide nucleic acid oligomers to engender a biological response 1 1998
6,989,270 Using polyamide nucleic acid oligomers to engender a biological response 0 1998
6,723,560 Using polyamide nucleic acid oligomers to engender a biological response 1 1998
* 2003/0109,537 Methods and materials for treating bone conditions 10 2002
* 2004/0009,899 Treating dominant disorders 0 2002
 
DAKO DENMARK A/S (9)
* 6,110,676 Methods for suppressing the binding of detectable probes to non-target sequences in hybridization assays 124 1997
6,962,778 Methods, kits and compositions for suppressing the binding of detectable probes to non-target sequences in hybridization assays 4 2000
* 2003/0124,521 Methods, kits and compositions for supressing the binding of detectable probes to non-target sequences in hybridization assays 3 2000
7,306,916 Methods for detecting chromosome aberrations 0 2005
* 2006/0078,904 Methods for detecting chromosome aberrations 0 2005
9,297,035 Compositions and methods for detection of chromosomal aberrations with novel hybridization buffers 0 2009
9,388,456 Compositions and methods for performing a stringent wash step in hybridization applications 0 2009
9,303,287 Compositions and methods for RNA hybridization applications 0 2009
9,309,562 Compositions and methods for performing hybridizations with separate denaturation of the sample and probe 0 2010
 
The Research Foundation of State University of New York (3)
* 9,150,612 RNA targeting compounds and methods for making and using same 0 2008
* 2008/0227,213 RNA targeting compounds and methods for making and using same 5 2008
9,260,476 RNA targeting compounds and methods for making and using same 0 2013
 
Obe Therapy Biotechnology S.A.S. (1)
* 2007/0298,025 Pharmaceutical Compositions and Methods for Reducing Body Fat 6 2007
 
ARC MEDICAL DEVICES, INC. (1)
* 2011/0104,295 PHARMACEUTICAL COMPOSITIONS AND METHODS RELATING TO INHIBITING FIBROUS ADHESIONS OR INFLAMMATORY DISEASE USING LOW SULPHATE FUCANS 1 2010
 
HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (6)
7,429,489 Methods of controlling proliferation and differentiation of stem and progenitor cells 1 2004
* 2005/0118,150 Methods of controlling proliferation and differentiation of stem and progenitor cells 2 2004
7,312,078 Methods of controlling proliferation and differentiation of stem and progenitor cells 4 2005
* 2005/0214,262 Methods of controlling proliferation and differentiation of stem and progenitor cells 2 2005
7,855,075 Methods of controlling proliferation and differentiation of stem and progenitor cells 0 2008
8,202,724 Methods of controlling proliferation and differentiation of stem and progenitor cells 0 2010
 
SIEMENS HEALTHCARE DIAGNOSTICS INC. (1)
7,833,729 Method for detecting endometriosis in a patient sample 0 2009
 
CHILDRENS HOSPITAL LOS ANGELES (2)
7,951,785 NFIA in glial fate determination, glioma therapy and astrocytoma treatment 0 2008
* 2009/0087,434 NFIA IN GLIAL FATE DETERMINATION, GLIOMA THERAPY AND ASTROCYTOMA TREATMENT 0 2008
 
MYCOLOGICS, INC. (1)
6,716,625 Histidine kinases of Aspergillus and other fungal species, related compositions, and methods of use 0 2000
 
CHANG GUNG UNIVERSITY (2)
7,803,543 Methods and kits for the detection of nucleotide mutations using peptide nucleic acid as both PCR clamp and sensor probe 0 2007
* 2008/0176,226 METHODS AND KITS FOR THE DETECTION OF NUCLEOTIDE MUTATIONS USING PEPTIDE NUCLEIC ACID AS BOTH PCR CLAMP AND SENSOR PROBE 3 2007
 
CATERPILLAR INC. (1)
* 2009/0288,392 Engine system having particulate reduction device and method 5 2008
 
Swift Biosciences, Inc. (1)
8,889,350 Methods and compositions for isolating polynucleotides 0 2011
 
VANDERBILT UNIVERSITY (3)
6,312,956 Nuclear targeted peptide nucleic acid oligomer 20 1999
6,623,966 Nuclear targeted peptide nucleic acid oligomer 4 2001
9,273,949 Backscattering interferometric methods 0 2013
 
MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (1)
* 2003/0151,317 Brushless motor and method of manufacturing the brushless motor 1 2003
 
Recombinetics, Inc. (2)
9,074,224 Methods and compositions for targeted gene modification 0 2010
* 2011/0059,160 METHODS AND COMPOSITIONS FOR TARGETED GENE MODIFICATION 4 2010
 
YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (9)
* 2006/0008,464 Histone conjugates and uses thereof 0 2003
7,534,605 CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases 3 2005
* 2006/0019,340 CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases 3 2005
8,067,573 Nucleic acid agents for downregulating H19 and methods of using same 0 2006
* 2009/0143,321 NUCLEIC ACID AGENTS FOR DOWNREGULATING H19 AND METHODS OF USING SAME 1 2006
8,067,574 Nucleic acid agents for downregulating H19, and methods of using same 0 2008
7,928,083 H19 silencing nucleic acid agents for treating rheumatoid arthritis 0 2008
* 2010/0196,403 ANTIBODY CONJUGATES FOR CIRCUMVENTING MULTI-DRUG RESISTANCE 0 2008
8,193,311 CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases 0 2011
 
PRESIDENT AND FELLOWS OF HARVARD COLLEGE (20)
7,070,928 Evolving new molecular function 23 2002
* 2003/0113,738 Evolving new molecular function 34 2002
7,183,054 Assay for identifying biological targets of polynucleotide-binding compounds 0 2003
* 2004/0248,100 Assay for identifying biological targets of polynucleotide-binding compounds 1 2003
7,491,494 Evolving new molecular function 23 2003
* 2004/0180,412 Evolving new molecular function 12 2003
7,557,068 Evolving new molecular function 14 2003
7,122,549 Saframycins, analogues and uses thereof 0 2004
7,771,935 Evolving new molecular function 14 2004
7,223,545 Evolving new molecular function 19 2004
* 2005/0170,376 Evolving new molecular function 18 2004
* 2005/0142,583 Evolving new molecular function 9 2004
7,998,904 Evolving new molecular function 10 2005
7,442,160 Evolving new molecular function 14 2005
* 2005/0233,381 Evolving new molecular 11 2005
* 2005/0227,281 Evolving new molecular function 2 2005
8,017,323 Free reactant use in nucleic acid-templated synthesis 2 2006
* 2006/0223,086 Free reactant use in nucleic acid-templated synthesis 10 2006
8,206,914 Evolving new molecular function 0 2010
* 2011/0190,141 Evolving New Molecular Function 2 2010
* Cited By Examiner